Research
Correction to "Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans" by Weiss et al. (2023).
Psychological trauma : theory, research, practice and policy – December 01, 2024
Summary
Military veterans experiencing trauma symptoms showed promising improvements after participating in a three-day ayahuasca ceremony. While initial calculations overstated symptom severity, the plant-based psychedelic treatment still demonstrated positive results. Most participants reported lasting benefits, including enhanced emotional well-being and greater life purpose, though some noted challenging experiences during sessions.
Abstract
Reports an error in "Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans"...
MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Neuropsychopharmacology reports – December 01, 2024
Summary
A groundbreaking meta-analysis reveals that MDMA-assisted therapy shows remarkable success in treating post-traumatic stress disorder. Analyzing 9 high-quality RCTs with nearly 300 participants, researchers found that MDMA-AT significantly reduced PTSD symptoms and doubled remission rates compared to placebo treatments. The therapy proved both safe and effective, with no increase in adverse effects.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating ...
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.
Current psychiatry reports – December 01, 2024
Summary
Promising breakthroughs in psychedelic medicine show that psilocybin and LSD may effectively treat both alcohol use disorder and major depressive disorder simultaneously. These conditions frequently occur together, making traditional treatments challenging. Studies reveal that psilocybin therapy significantly reduces drinking frequency and depressive symptoms, offering hope for a unified treatment approach.
Abstract
In this narrative review, we discuss evidence for psilocybin- and LSD-assisted treatment of alcohol use disorder (AUD) and major depressive disorde...
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder.
CNS drugs – December 01, 2024
Summary
Breakthrough research reveals that boosting specific brain receptors (NMDARs) may offer a safer alternative to current depression treatments. While ketamine blocks these receptors and works quickly, it carries risks. New drugs that enhance NMDAR activity show promise in treating depression with fewer side effects. This approach could revolutionize treatment for millions, offering faster relief without the drawbacks of existing medications.
Abstract
Major depressive disorder (MDD) is a severe mental illness with a complex etiology. Currently, many medications employed in clinical treatment exhi...
Treatment-resistant depression: Established and emerging therapies.
The Nurse practitioner – December 01, 2024
Summary
When traditional antidepressants fail, innovative therapies offer new hope. For patients with treatment-resistant depression, breakthrough treatments like ketamine and esketamine show rapid improvement in mood. While electroconvulsive therapy remains highly effective, newer options like transcranial magnetic stimulation provide gentler alternatives with fewer side effects and promising success rates.
Abstract
In 2023, the percentage of people in the US who experienced depression in their lifetime was at an all-time high of 29%. Depression causes consider...
Connected through movement: a feasibility study of online mindfulness-based dance/movement therapy for older adults with age-related cognitive decline during COVID-19.
Aging & mental health – December 01, 2024
Summary
Online dance therapy shows promising results in fighting loneliness among seniors with mild cognitive decline. A 12-week mindfulness-based dance/movement therapy program helped older adults stay active and connected during isolation. Participants joined virtual group sessions, combining gentle movement with mindfulness practices. Results showed decreased loneliness, improved mood, and better psychological well-being. 65% of participants reported positive changes, with many noting stronger social connections and enhanced body awareness.
Abstract
Social isolation and loneliness pose significant public health risks, especially among older adults experiencing age-related cognitive decline (ACD...
Navigating Treatment-Resistant Major Depressive Disorder With Suicidal Ideation: Exploring the Efficacy of Spravato (Esketamine) in an 86-Year-Old Male.
Cureus – December 01, 2024
Summary
An 86-year-old patient achieved remarkable recovery from severe depression using esketamine nasal spray after multiple traditional treatments failed. This groundbreaking case in geriatric psychiatry showed how the medication effectively treated both major depressive disorder (MDD) and suicidal thoughts in an elderly patient. The treatment proved safe and highly effective, marking a significant advance in helping older adults with treatment-resistant depression.
Abstract
This case study examines the novel application of Spravato (intranasal esketamine) to address treatment-resistant Major Depressive Disorder (MDD) i...
Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.
The international journal of neuropsychopharmacology – December 01, 2024
Summary
A groundbreaking treatment for severe depression shows remarkable safety profile: Esketamine nasal spray causes minimal breathing concerns in real-world use. Analysis of 47 months of data reveals only 1 case of respiratory depression per 20,000 treatments. When issues occur, they're easily managed with basic monitoring and resolve quickly with simple supportive care.
Abstract
Esketamine nasal spray (ESK) is approved, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression in adults...
Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.
Psychiatry research – December 01, 2024
Summary
Adding dextromethorphan to standard antidepressants doubled the remission rate in people with major depressive disorder. This groundbreaking finding shows how a common cough suppressant could enhance depression treatment. The 8-week trial found patients receiving adjunct therapy with dextromethorphan showed significantly better response rates and symptom improvement compared to those on standard treatment alone, with minimal side effects.
Abstract
Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major depressive disorde...
Pharmacotherapeutic strategies for the treatment of anorexia nervosa - novel targets to break a vicious cycle.
Expert opinion on pharmacotherapy – December 01, 2024
Summary
Despite being the deadliest eating disorder, anorexia nervosa may soon have new treatment options. Emerging research shows promising results using innovative approaches like ketamine, psychedelics, and ketogenic nutrition alongside traditional therapies. These treatments target both the neurobiological basis of anorexia and common co-occurring conditions like anxiety and depression.
Abstract
Anorexia nervosa (AN) has one of the highest mortality rates of all mental illnesses. No approved pharmacological treatments exist for AN, but nove...
Effect of intravenous esketamine in emergency cesarean deliveries: a retrospective analysis of maternal and neonatal outcomes.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians – December 01, 2024
Summary
Esketamine shows promise in emergency cesarean sections, offering better blood pressure control for mothers without compromising newborn health. This medication helped maintain stable maternal blood pressure during critical moments of surgery, while babies showed normal health indicators and even better blood pH levels. Though some mothers experienced mild side effects like dizziness, the overall maternal and neonatal outcomes were positive, suggesting a safe option for emergency C-section care.
Abstract
This study investigates the effects of administering intravenous esketamine at a dose of 0.25 mg/kg to pregnant patients receiving epidural anesthe...
Ketamine modulates the exploratory dynamics and homebase-related behaviors of adult zebrafish.
Pharmacology, biochemistry, and behavior – December 01, 2024
Summary
Ketamine, a common anesthetic, shows promising effects in reducing anxiety-like behaviors in zebrafish. When exposed to low doses, fish displayed more confident exploration patterns and reduced wall-hugging behavior in open field tests. The drug, which blocks NMDA receptors in the brain, increased movement while decreasing repetitive behaviors over time, suggesting potential therapeutic benefits beyond its traditional use.
Abstract
Anxiety can be a protective emotion when animals face aversive conditions, but is commonly associated with various neuropsychiatric disorders when ...
Esketamine use for primary intelligent analgesia in adults with severe burns: A double-blind randomized trial with effects on analgesic efficacy, gastrointestinal function and mental state.
Burns : journal of the International Society for Burn Injuries – December 01, 2024
Summary
Breakthrough pain management: Esketamine shows promise in treating severe burn victims, reducing opioid needs by up to 30%. This innovative approach combines primary intelligent analgesia with Esketamine, improving pain control while maintaining gastrointestinal function. Patients reported better subjective analgesic efficacy and sleep quality, marking a significant advance in burn care treatment.
Abstract
Opioid consumption for analgesia in burn patients is enormous. Non-opioid analgesics for burn pain management may result in opioid sparing, reducin...
Ketamine-induced cystitis: A case report and literature review.
Radiology case reports – December 01, 2024
Summary
Chronic recreational ketamine use can trigger severe bladder damage, as revealed in a striking medical case. A patient's daily ketamine habit led to cystitis with symptoms including blood in urine and bladder thickening. Through specialized ureteropyeloscopy, doctors confirmed extensive urinary tract damage. After stopping ketamine use and receiving targeted treatment, the patient recovered successfully, highlighting how early intervention can reverse drug-induced bladder problems.
Abstract
Ketamine, a dissociative anesthetic drug, has gained popularity as a recreational substance, particularly among young adults. However, chronic keta...
Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration.
Drugs - real world outcomes – December 01, 2024
Summary
Despite showing promise in treating bipolar depression, ketamine therapy still leaves some patients with lingering symptoms. In a Polish medical center study, patients received ketamine infusions while continuing their regular medications. Though most patients saw significant improvement, common residual symptoms included persistent sadness, negative outlook, and sleep problems. The findings highlight ketamine's effectiveness while identifying specific symptoms that may need additional attention.
Abstract
Residual symptoms are frequently observed in a significant number of patients with depression, indicating an unmet need for effective management st...
Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – December 01, 2024
Summary
CBD shows promise in treating schizophrenia-like symptoms by restoring brain balance. Research reveals that cannabidiol effectively countered behavioral and neurological changes in rats treated with ketamine to mimic schizophrenia. The compound worked by normalizing brain activity in key regions, particularly the prefrontal cortex and hippocampus, helping restore proper neurotransmitter function.
Abstract
Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiologi...
A brief review of complex regional pain syndrome and current management.
Annals of medicine – December 01, 2024
Summary
Chronic pain that spreads beyond an initial injury affects 200,000 Americans yearly. Treatment options have expanded dramatically, combining traditional medications like gabapentin and ketamine with innovative therapies. Doctors now use precise diagnostic tools (Budapest criteria) to identify this condition early. Advanced treatments include spinal cord stimulation, nerve blocks, and botulinum toxin injections. While severe cases may require amputation, most patients improve with early intervention and antioxidant therapy.
Abstract
Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition that, although exceedingly rare, carries a significant burden for th...
Meditation for Anxiety: A Holistic Approach to Treatment.
Journal of holistic nursing : official journal of the American Holistic Nurses' Association – December 01, 2024
Summary
No Summary
Abstract
This comprehensive integrated literature review provides evidence-based information on mindfulness meditation as a primary care treatment for anxie...
Low-dose ketamine for acute pain: A narrative review.
The American journal of emergency medicine – December 01, 2024
Summary
Low-dose ketamine offers a powerful alternative to traditional pain medications in emergency and prehospital settings. Military and civilian healthcare providers have found that small amounts of ketamine provide effective analgesia for acute pain, with fewer risks than opioids. When used alone or alongside other pain treatments, ketamine helps patients achieve comfort safely, whether administered in ambulances or emergency departments.
Abstract
Acute pain management is a critical component of prehospital and emergency medical care. Opioids are effective; however, the risks and side-effects...
Mace Poisoning: Accidental Toxic Ingestion in a Child Leading to a Reversible Coma.
Cureus – December 01, 2024
Summary
No Summary
Abstract
Nutmeg and mace are commonly known for their medicinal and culinary properties. The chemical compounds found in nutmeg and mace, notably myristicin...
The role of ketamine and its enantiomer in managing depression and pain in cancer patients: A narrative review.
Journal of anesthesia and translational medicine – December 01, 2024
Summary
Ketamine, traditionally used in anesthesia, emerges as a powerful dual solution for cancer patients struggling with both depression and pain. This innovative approach shows rapid mood improvement and effective pain management in oncology settings. Low doses can significantly reduce depressive symptoms while also helping control post-surgical discomfort, offering cancer patients a more comfortable recovery journey.
Abstract
Depression and pain are common comorbidities in cancer patients, and ketamine, a dissociative anesthetic, has shown potential in managing both. Thi...
The Spiral of Attention, Arousal, and Release: A Comparative Phenomenology of Jhāna Meditation and Speaking in Tongues.
American journal of human biology : the official journal of the Human Biology Council – December 01, 2024
Summary
No Summary
Abstract
Buddhist Jhāna meditation and the Christian practice of speaking in tongues appear wildly distinct. These spiritual techniques differ in their ethi...
Change starts with the body: Interoceptive appreciation mediates the effect of mindfulness training on behavior change - an effect moderated by depression severity.
Psychiatry research – December 01, 2024
Summary
No Summary
Abstract
Mindfulness catalyzes health behavior change. Yet, interoception is dysregulated in depression, potentially impairing behavioral activation. We exa...
Online Mindfulness-Based Intervention (eMBI) in management of dyspnea in patients with interstitial lung disease: A randomized clinical trial.
Complementary therapies in medicine – December 01, 2024
Summary
No Summary
Abstract
Dyspnea and cough are frequent symptoms in ILD patients. The management of these symptoms is challenging, and evidence-based therapies are lacking....
Transcendental Meditation Enriches Nurses' Authentic Presence Through Caring for Self and Others.
Journal of holistic nursing : official journal of the American Holistic Nurses' Association – December 01, 2024
Summary
No Summary
Abstract
Purpose of Study: Given the enormity of the most recent challenges to clinician well-being, intensified by the pandemic, we decided to explore the ...
Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.
Journal of the American Academy of Child and Adolescent Psychiatry – December 01, 2024
Summary
Groundbreaking research explores psychedelic-assisted therapy as a potential treatment for treatment-resistant mental health conditions in older teens. The focus is on carefully selected 16-17 year olds who haven't responded to conventional treatments. Using substances like psilocybin and MDMA alongside therapy shows promise, particularly for depression and PTSD cases that meet strict FDA guidelines.
Abstract
Youth today are burdened by significant mental health challenges. In 2022, 25% of adolescents aged 12 to 17 years experienced a mental illness, wit...
From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.
British journal of clinical pharmacology – December 01, 2024
Summary
No Summary
Abstract
The rise of psychedelics in contemporary medicine has sparked interest in their potential therapeutic applications. While traditionally associated ...
Low-Dose LSD Alters Early and Late Event-Related Potentials to Emotional Faces.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2024
Summary
A tiny dose of LSD can change how our brains process emotional faces, according to groundbreaking EEG research. Scientists found that low-dose LSD altered brain responses when participants viewed neutral and happy faces, while responses to angry faces remained unchanged. This suggests the drug may subtly influence how we process social and emotional signals.
Abstract
Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these do...
Tags
Beyond psychedelics: set and setting in general psychiatric practice.
International review of psychiatry (Abingdon, England) – December 01, 2024
Summary
No Summary
Abstract
Psychedelic compounds continue gaining scientific and regulatory traction as potential new treatments for psychiatric disorders. While most psychia...
Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
Pharmacological reports : PR – December 01, 2024
Summary
Psilocybin shows remarkable potential in treating depression by triggering a cascade of brain chemistry changes. The compound works by activating 5-HT2A receptors in the brain, which increases glutamate release. This boost in glutamate leads to higher GABA activity, creating a balanced brain state that helps alleviate depressive symptoms and promotes neural adaptability.
Abstract
In recent decades, psilocybin has gained attention as a potential drug for several mental disorders. Clinical and preclinical studies have provided...
Safety and efficacy of ketamine use in patients with vaso-occlusive crisis: A systematic review and meta-analysis.
EJHaem – December 01, 2024
Summary
Ketamine shows promise as an alternative to traditional opioids for managing severe pain in sickle cell disease. When painful vaso-occlusive crises strike, this medication could offer relief while reducing opioid dependence. Analysis of nearly 700 patients revealed that ketamine was generally safe, with only mild side effects like nausea. While pain reduction scores were similar to standard treatments, ketamine provided effective pain management without serious complications.
Abstract
Sickle cell disease (SCD) is characterized by acute episodes called vaso-occlusive crises (VOC). VOC is marked by severe pain due to blocked blood ...
Zen Den: A Novel Approach to Promote Well-Being in the Workplace.
Journal of holistic nursing : official journal of the American Holistic Nurses' Association – December 01, 2024
Summary
No Summary
Abstract
Purpose: In response to the COVID-19 pandemic, holistic nurses at an academic level 1 trauma center in Hawaii utilized a novel holistic approach to...
Exploring the regulatory framework of psychedelics in the US & Europe.
Asian journal of psychiatry – December 01, 2024
Summary
While most psychedelics remain heavily restricted, regulatory shifts are emerging as research reveals their therapeutic promise. The US and EU are developing frameworks to evaluate substances like psilocybin, LSD, and MDMA for mental health treatment. Ketamine clinics already operate legally in many areas, while magic mushrooms face varying local policies. New laws aim to balance patient access with safety controls.
Abstract
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic...
Tags
Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment.
Pharmacological reports : PR – December 01, 2024
Summary
Ketamine therapy's impact on sleep patterns in people with treatment-resistant depression reveals unexpected findings. While this promising depression treatment helps many patients, a group of 28 individuals receiving ketamine infusions showed no significant changes in their sleep patterns - including issues like insomnia and early morning waking. This challenges previous research suggesting ketamine improves sleep quality during treatment.
Abstract
This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administratio...
God hasn’t died, it has merely been encapsulated – Psilocybin and ayahuasca in the psychedelic renaissance: Intersections between religion, indigenous cosmologies, spirituality, and science
Social Compass – December 01, 2024
Summary
Ayahuasca and psilocybin, powerful hallucinogens, are undergoing distinct secularization processes. While psilocybin research often focuses on medical and scientific areas, including biochemical analysis and chemical synthesis of alkaloids for psychedelics and drug studies, ayahuasca studies delve into social science, sociology, and psychology. Ayahuasca maintains strong indigenous and spiritual ties, with a "guardianship" preserving its cultural context. Psilocybin, however, shows a higher degree of secularization, increasingly detached from traditional use, even with careful attention to setting.
Abstract
This article traces the trajectories of psilocybin and ayahuasca in the context of the psychedelic renaissance. The bibliometric analysis reveals t...
Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022.
Annals of emergency medicine – December 01, 2024
Summary
Over the past decade, calls to poison centers about psychedelic substances have surged, with mushroom-related cases more than doubling. Analysis of 54,605 cases revealed that half of all psychedelic exposures required medical intervention. Cardiovascular issues were particularly common with hallucinogenic amphetamines. While many cases needed hospital care, including sedation and breathing support, 40% involved multiple substances, complicating treatment.
Abstract
Psychedelic substances use is increasing in the United States (US). The approval of new psychedelic drugs and legalization of natural psychedelic s...
The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP).
Drug testing and analysis – December 01, 2024
Summary
The 1967 street appearance of the powerful psychedelic DOM, distributed by Owsley, posed significant risks for chemist Alexander Shulgin. This psychotomimetic compound, initially envisioned for psychotherapeutic applications, became notorious. Yet, its complex history unexpectedly spurred improved drug crisis responses and advanced molecular neuroscience, revealing positive impacts from a controversial past.
Abstract
The story of the 1967 appearance of the powerful psychedelic 2,5-dimethoxy-4-methylamphetamine (DOM, STP) commonly omits details and often includes...
Learning how to make use of dissociative therapies.
International review of psychiatry (Abingdon, England) – December 01, 2024
Summary
Breakthrough treatments like ketamine and esketamine are transforming mental health care through their rapid-acting effects. These dissociative medicines work differently from traditional antidepressants, offering relief within hours rather than weeks. While related to psychedelic therapy, they have unique properties. Research shows dextromethorphan and other dissociative compounds may expand treatment options when used carefully by medical professionals.
Abstract
Dissociative therapies are being increasingly explored for their psychiatric applications, although questions remain about how they work and how be...
Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices.
British journal of clinical pharmacology – December 01, 2024
Summary
Psychedelic compounds like dimethyltryptamine (DMT) and ayahuasca are showing promise in treating chronic pain and mental health conditions. Anesthesiologists play a crucial role in administering these substances safely, monitoring patients, and managing potential psychedelic toxicity. Research reveals these treatments can be effective when properly supervised, with protocols focusing on careful screening, dosing, and medical oversight.
Abstract
Recent years have witnessed an unprecedented increase in the search for the use of psychedelics in improving physical and mental health. Anaesthesi...
Psilocybin and hallucinogenic mushrooms
CNS Spectrums – December 01, 2024
Summary
Psilocybin, a potent hallucinogen, is emerging as a promising treatment in Medicine for depression. Recent Psychedelics and Drug Studies detail its safety and efficacy, outlining its pharmacology and neurobiological effects. This naturally occurring alkaloid, often explored alongside compounds in Cannabis and Cannabinoid Research, is delivered with specific protocols. Understanding its chemical synthesis is vital. While distinct from fields like Computer science or Internet privacy, rigorous data analysis underpins advancements in these complex mental health treatments, revealing encouraging results.
Abstract
Abstract Psilocybin therapy has recently emerged as a promising new treatment for depression and other mental health disorders. This chapter summar...
The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.
CNS spectrums – December 01, 2024
Summary
Psilocin, the active compound in magic mushrooms, shows remarkable potential as one of nature's rapid-acting antidepressants. Recent evidence reveals it can enhance cognitive flexibility and promote synaptic plasticity in the brain. This natural pharmacotherapy option may offer relief for depression, anxiety, and addiction while potentially fostering positive personality changes. Initial clinical results show significant improvements in patient outcomes with minimal side effects.
Abstract
The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other p...
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty.
Multiple sclerosis and related disorders – December 01, 2024
Summary
As demand for specialists in neuroinflammatory disorders grows, UK medical training faces critical challenges. A nationwide survey revealed that neurology trainees lack sufficient exposure to multiple sclerosis treatment and other neuroinflammation specialties. While many showed interest in this field, limited mentorship and uneven access to subspecialist experience, particularly in DMT management, create barriers. Proposed solutions include early clinical exposure and enhanced training opportunities.
Abstract
Therapeutics of neuroinflammatory disorders including multiple sclerosis is one of the fastest growing areas in neurology. However, pressures on hi...
Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats.
Pharmacology, biochemistry, and behavior – December 01, 2024
Summary
Mescaline, a natural psychedelic, affects brain chemistry through specific serotonin receptors. New findings reveal how this compound influences behavior by targeting two key receptor types. When given to rats, mescaline altered both locomotor activity and sensorimotor gating. Blocking certain serotonin receptors prevented these changes, showing that mescaline's effects primarily work through 5-HT2A receptors, with secondary involvement of 5-HT2C receptors.
Abstract
Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds...
The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.
Journal of psychiatric research – December 01, 2024
Summary
Challenging conventional wisdom, stopping antidepressants before psilocybin therapy doesn't reduce its effectiveness in treating severe depression. In a groundbreaking clinical trial with 233 participants, researchers found that people who discontinued antidepressants responded just as well to psilocybin treatment as those who were medication-free. The psychedelic experience and therapeutic benefits remained strong for all participants, regardless of prior medication status.
Abstract
It has been suggested that the recent use and discontinuation of antidepressant drugs compromises the action of psilocybin. As evidence is only ava...
Mindfulness-based intervention as a symptom management strategy in patients with end-stage renal disease: A controlled clinical trial.
International journal of nursing practice – December 01, 2024
Summary
No Summary
Abstract
The study's purpose was to examine the effect of mindfulness-based intervention (MBI) on physical and psychological symptoms in patients with end-s...
Abnormal resting-state functional connectivity of the right anterior cingulate cortex in chronic ketamine users and its correlation with cognitive impairments.
Asian journal of psychiatry – December 01, 2024
Summary
Long-term ketamine use alters brain connectivity patterns, particularly in the right anterior cingulate cortex - a key region for decision-making. Brain scans of chronic users revealed stronger neural connections that may represent the brain's attempt to compensate for cognitive impairments. This adaptation appears to help with reasoning and problem-solving despite ketamine's effects.
Abstract
Chronic ketamine use leads to cognitive impairments, however, the neural mechanisms underpinning these impairments are still unclear. Many studies ...
Treating psychological trauma: Special populations, symptoms, and innovative models of care.
Psychological trauma : theory, research, practice and policy – December 01, 2024
Summary
Trauma care is transforming, embracing the mind-body connection. New insights reveal that successful trauma care is increasingly **holistic** and **integrative**, recognizing individual **resilience**. Approaches now span from **mindfulness** and arts to physical activity and even carefully considered **psychedelics**, all aimed at healing diverse populations. This broadens effective options, emphasizing positive outcomes by tailoring care to individual needs and inherent strengths.
Abstract
Trauma treatment continues to evolve, with a wider range of options than ever before. In recent years, trauma treatments have become more holistic ...
Serotonergic transmission plays differentiated roles in the rapid and sustained antidepressant-like effects of ketamine.
British journal of pharmacology – December 01, 2024
Summary
Ketamine's remarkable ability to lift depression quickly has opened new doors in mental health treatment. Recent findings reveal that serotonin (5-HT) plays a crucial role in how this fast-acting antidepressant works. While ketamine's initial effects occur independently, its sustained benefits rely heavily on serotonin transmission and AMPA receptor activation in the brain, suggesting a complex mechanism behind its long-lasting antidepressant properties.
Abstract
The emerging antidepressant effects of ketamine have inspired tremendous interest in its underlying neurobiological mechanisms, although the involv...
The quest for optimal ketamine dosing formula in treatment-resistant major depressive disorder.
Pharmacological reports : PR – December 01, 2024
Summary
Ketamine shows remarkable promise in treating stubborn depression, with success rates tied closely to precise dosing. New research reveals that traditional weight-based dose calculations may be more effective than alternative methods using lean body mass or body surface area. When treating major depressive disorder, the standard dose of 0.5mg/kg provides better coverage than formulas based on ideal body weight or other metrics.
Abstract
Emerging evidence indicates that intravenous ketamine is effective in managing treatment-resistant unipolar and bipolar depression. Clinical studie...
Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – December 01, 2024
Summary
Different forms of MDMA affect the brain and body in unique ways, with the S-form showing stronger mood-enhancing effects than its mirror image, the R-form. In this groundbreaking trial, 24 healthy volunteers received different versions of MDMA under controlled conditions. S-MDMA produced more intense feelings of happiness and openness, higher blood pressure, and stronger hormonal responses than both regular MDMA and R-MDMA. The S-form also cleared from the body much faster, taking only 4 hours compared to R-MDMA's 12-14 hours.
Abstract
Racemic 3,4-methylenedioxymethamphetamine (MDMA) acutely increases mood, feelings of empathy, trust, and closeness to others and is investigated to...
Genetic ablation of the isoform γ of PI3K decreases antidepressant efficacy of ketamine in male mice.
IBRO neuroscience reports – December 01, 2024
Summary
A protein called PI3Kγ plays a crucial role in how well ketamine and other antidepressants work. When this protein is missing, mice show no improvement in coping behavior when treated with ketamine - a promising rapid-acting treatment for major depressive disorder. This discovery helps explain why some patients don't respond to antidepressants and could lead to better treatment matching.
Abstract
About one-third of major depressive disorder (MDD) patients demonstrate unresponsiveness to classic antidepressants, and even the clinical efficacy...
Intravenous Ketamine for Cancer Pain: A Single-Center Retrospective Analysis Comparing Fixed-Rate Versus Weight-Based Dosing.
Journal of pain & palliative care pharmacotherapy – December 01, 2024
Summary
Ketamine offers new hope for cancer-related pain management, with nearly half of patients experiencing significant relief. A groundbreaking analysis reveals that simpler fixed-rate dosing works just as effectively as more complex weight-based calculations. Patients with higher initial opioid needs showed better response to ketamine therapy, suggesting it's particularly valuable for those with severe pain. The findings point to streamlined treatment options that could make pain relief more accessible.
Abstract
Although weak evidence exists to support subanesthetic ketamine for cancer pain treatment, successful use may be hindered in the absence of standar...
Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta‐analyses of randomized controlled trials
Psychiatry and Clinical Neurosciences Reports – December 01, 2024
Summary
Psilocybin, a potent hallucinogen, and Ketamine, used in Anesthesia and Pharmacology, show superior antidepressant effects for Major depressive disorder compared to theta burst stimulation. A meta-analysis of 28 Randomized controlled trials revealed both drugs, central to Psychedelics and Drug Studies, surpassed Placebo. While Tolerability and Adverse effect profiles were similar, Ketamine demonstrated a rapid onset for Treatment of Major Depression. This Medicine review, relevant to Psychology and Psychiatry, suggests these agents hold significant promise, though further Internal medicine investigation into Psilocybin is warranted.
Abstract
Abstract The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressiv...
Comparing the hemodynamic effects of ketamine versus fentanyl bolus in patients with septic shock: a randomized controlled trial.
Journal of anesthesia – December 01, 2024
Summary
In critical care settings, choosing the right sedation medication can significantly impact patient outcomes. Ketamine showed remarkable benefits over fentanyl in patients with septic shock, increasing cardiac output by 71% compared to a 31% decrease with fentanyl. The research tracked vital signs in mechanically ventilated patients, revealing ketamine's superior ability to maintain stable blood pressure and heart function during sedation.
Abstract
Ketamine and fentanyl are commonly used for sedation and induction of anesthesia in critically ill patients. This study aimed to compare the hemody...
Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.
Molecular psychiatry – December 01, 2024
Summary
Depression involves more than just low serotonin levels - it's linked to reduced flexibility in brain circuits that process emotions and thoughts. Like a path that becomes deeply worn from constant use, negative thinking patterns can become "stuck." Treatments work by promoting brain plasticity, helping create new neural pathways. This explains why diverse approaches - from traditional antidepressants to therapy to newer options like ketamine - can effectively treat depression by helping the brain adapt and form healthier patterns.
Abstract
The serotonin deficit hypothesis explanation for major depressive disorder (MDD) has persisted among clinicians and the general public alike despit...
Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.
Psychiatry and clinical neurosciences – December 01, 2024
Summary
A groundbreaking study reveals that ketamine shows promise in treating depression across ethnic groups, with Japanese patients experiencing significant mood improvements after repeated doses. In this first major Asian trial, patients with treatment-resistant depression received twice-weekly ketamine infusions for two weeks. Those completing the full treatment showed meaningful reduction in depression symptoms compared to placebo, with higher initial depression scores predicting better outcomes. The treatment proved safe, with no serious side effects reported.
Abstract
Although the antidepressant effect of ketamine on treatment-resistant depression (TRD) has been frequently reported in North American and European ...
General Anesthesia Occludes Ketamine's Antidepressant Response in a Rodent Model of Chronic Stress.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2024
Summary
Ketamine's antidepressant effects may depend on being conscious during treatment, new research reveals. When mice under general anesthesia received ketamine, they didn't experience the drug's typical antidepressant response. The findings suggest that being awake during ketamine therapy—including its dissociative subjective effects—could be crucial for relieving chronic stress and depression.
Abstract
Psychedelic-induced experiences are thought to play an important role in the therapeutic actions of rapid-acting antidepressants. General anesthesi...
Dissociative Trance Led to a Catastrophe: A Case Report.
Cureus – December 01, 2024
Summary
No Summary
Abstract
Dissociation is a cognitive process that disrupts consciousness, identity, or memory. It is frequently used as a form of defense in response to sig...
Considering distinct positive emotions in psychedelic science.
International review of psychiatry (Abingdon, England) – December 01, 2024
Summary
No Summary
Abstract
In this review, we discuss psychedelics' acute subjective and persisting therapeutic effects, outline the science of positive emotions, and highlig...
Tags
Intraoperative ketamine and pain after video-assisted thoracoscopic surgery (VATS): A systematic review and meta-analysis.
Anaesthesia, critical care & pain medicine – December 01, 2024
Summary
Effective pain relief after surgery significantly speeds recovery. A comprehensive meta-analysis investigated whether intraoperative Ketamine could reduce acute pain following Video-assisted thoracoscopic surgery. This review of multiple studies revealed that Ketamine effectively reduced postoperative pain at both 12 and 48 hours, offering a promising approach for enhanced patient comfort.
Abstract
Video-assisted thoracoscopic surgery (VATS) reduces postoperative discomfort and expedites recovery compared to open thoracotomy. Effective postope...